CN102688492A - 包含四环素类的抗炎组合物及其用途 - Google Patents

包含四环素类的抗炎组合物及其用途 Download PDF

Info

Publication number
CN102688492A
CN102688492A CN2012101925621A CN201210192562A CN102688492A CN 102688492 A CN102688492 A CN 102688492A CN 2012101925621 A CN2012101925621 A CN 2012101925621A CN 201210192562 A CN201210192562 A CN 201210192562A CN 102688492 A CN102688492 A CN 102688492A
Authority
CN
China
Prior art keywords
compositions
tetracycline
compound
intestinal
tetracyclines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101925621A
Other languages
English (en)
Chinese (zh)
Inventor
P·乔姆科辛斯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR RES CT Inc
Original Assignee
MOLECULAR RES CT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR RES CT Inc filed Critical MOLECULAR RES CT Inc
Publication of CN102688492A publication Critical patent/CN102688492A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
CN2012101925621A 2007-03-23 2008-03-20 包含四环素类的抗炎组合物及其用途 Pending CN102688492A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89656407P 2007-03-23 2007-03-23
US60/896,564 2007-03-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880016401A Division CN101678108A (zh) 2007-03-23 2008-03-20 包含四环素类的抗炎组合物及其用途

Publications (1)

Publication Number Publication Date
CN102688492A true CN102688492A (zh) 2012-09-26

Family

ID=39651298

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012101925621A Pending CN102688492A (zh) 2007-03-23 2008-03-20 包含四环素类的抗炎组合物及其用途
CN200880016401A Pending CN101678108A (zh) 2007-03-23 2008-03-20 包含四环素类的抗炎组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880016401A Pending CN101678108A (zh) 2007-03-23 2008-03-20 包含四环素类的抗炎组合物及其用途

Country Status (9)

Country Link
US (1) US20080233206A1 (https=)
EP (1) EP2125018A1 (https=)
JP (1) JP5395052B2 (https=)
KR (2) KR20130137696A (https=)
CN (2) CN102688492A (https=)
AP (1) AP2657A (https=)
AU (1) AU2008231033B2 (https=)
EA (1) EA016206B1 (https=)
WO (1) WO2008118744A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110169973A (zh) * 2019-06-11 2019-08-27 贾树森 一种用于颈椎康复的外用药物组合物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261143B2 (en) 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
PT2568987T (pt) * 2010-05-12 2017-02-03 Rempex Pharmaceuticals Inc Composições de tetraciclina
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
PT106679B (pt) * 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
ITMI20132066A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
WO2015153864A2 (en) * 2014-04-02 2015-10-08 Hopkins Patricia T Methods for treating inflammatory conditions
CN103933539B (zh) * 2014-04-16 2017-01-11 西北农林科技大学 一种含有四环素的药物组合物及其应用
MX2017012062A (es) 2015-03-23 2018-06-18 Biopharmx Inc Composicion farmaceutica de tetraciclina para uso dermatologico.
CN105998037A (zh) * 2016-06-16 2016-10-12 汕头大学 多西环素在制备治疗或预防衰老性疾病的药物中的用途
CO2017001953A1 (es) * 2017-02-27 2018-08-31 Corporacion Univ Lasallista Método de encapsulación de tetraciclinas
MY203238A (en) * 2018-10-29 2024-06-19 Fraunhofer Ges Zur Frderung Der Angewandten Forschung E V Tetracycline complexes with sustained activity
CN111870607A (zh) * 2020-07-09 2020-11-03 温州医科大学 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法
KR102855121B1 (ko) * 2021-12-17 2025-09-04 주식회사 케이씨앤씨 클로르테트라사이클린을 포함하는 고양이 전염성 복막염 치료용 조성물
CN116655491B (zh) * 2023-05-12 2025-01-28 常州大学 一种多功能抗菌纳米材料TCFNPs及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736725A (en) * 1954-03-11 1956-02-28 American Cyanamid Co Complexes of tetracycline antibiotics and preparation of same
US2766124A (en) * 1954-05-25 1956-10-09 American Cyanamid Co Antibiotic-containing ice composition
US2806789A (en) * 1954-09-10 1957-09-17 American Cyanamid Co Enhancement of therapeutic efficacy of antibiotics
GB901209A (en) * 1957-10-23 1962-07-18 Pfizer & Co C 6-deoxytetracyclines and compositions containing same
GB901107A (en) * 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
GB894619A (en) * 1959-09-11 1962-04-26 Pfizer & Co C Stabilized liquid preparations comprising tetracycline antibiotics
FR1430859A (https=) * 1960-05-23 1966-05-25
US3275513A (en) * 1963-05-29 1966-09-27 American Cyanamid Co Stable calcium tetracycline compositions
US4061676A (en) * 1970-07-03 1977-12-06 Ivan Villax Recovery of doxycycline and products thereof
US3957980A (en) * 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
US4060605A (en) * 1973-09-28 1977-11-29 Ankerfarm, S.P.A. Water-soluble derivative of 6-deoxy-tetracyclines
DK153784C (da) * 1973-09-28 1989-01-23 Pfizer Analogifremgangsmaade til fremstilling af 2-n-(methioninomethyl)doxycyclin eller salte deraf
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS51107134A (en) * 1975-03-17 1976-09-22 Asahi Optical Co Ltd Shotenmenkenshutsusochi
US4081527A (en) * 1976-12-07 1978-03-28 Pfizer Inc. Chlortetracycline compositions
US4126680A (en) * 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US5538954A (en) * 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
DE69627855T2 (de) * 1995-06-13 2004-03-11 Nippon Meat Packers, Inc. Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
CA2360938C (en) * 1999-02-02 2008-01-08 Warren Oliver Haggard Controlled release composite
US6765000B2 (en) * 1999-03-17 2004-07-20 Bonner Jr Ernest L Treatment for reactive arthritis or bursitis
US7884090B2 (en) * 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US6638532B2 (en) * 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6887492B2 (en) * 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1383508B1 (en) * 2001-04-05 2006-06-21 Collagenex Pharmaceuticals, Inc. Doxycycline for the treatment of acne
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
US7122578B2 (en) * 2001-09-11 2006-10-17 Alain Martin Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
NO315915B1 (no) * 2002-02-25 2003-11-10 Sintef Elektronikk Og Kybernet Fj¶rvekt
JP2005533766A (ja) * 2002-05-20 2005-11-10 コッラジェネックス ファーマシューチカルス インコーポレイテッド アレルギー反応の治療方法
AU2004261143B2 (en) * 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
EP2033950A1 (en) * 2004-10-25 2009-03-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TING-FONG CHIN等: "drug diffusion and bioavailability: tetracycline metallic chelation", 《AMERICAN JOURNAL OF HOSPITAL PHARMACISTS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110169973A (zh) * 2019-06-11 2019-08-27 贾树森 一种用于颈椎康复的外用药物组合物

Also Published As

Publication number Publication date
AP2657A (en) 2013-05-07
AU2008231033A1 (en) 2008-10-02
AP2009004979A0 (en) 2009-10-31
KR20130137696A (ko) 2013-12-17
US20080233206A1 (en) 2008-09-25
KR20090122994A (ko) 2009-12-01
EA016206B1 (ru) 2012-03-30
JP2010522240A (ja) 2010-07-01
WO2008118744A1 (en) 2008-10-02
AU2008231033B2 (en) 2012-08-30
CN101678108A (zh) 2010-03-24
EA200901289A1 (ru) 2010-02-26
EP2125018A1 (en) 2009-12-02
JP5395052B2 (ja) 2014-01-22

Similar Documents

Publication Publication Date Title
CN102688492A (zh) 包含四环素类的抗炎组合物及其用途
Altarac et al. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women
US6656925B2 (en) Composition and method of treating arthritis
US20040162269A1 (en) Composition and method of treating arthritis
JP3806427B2 (ja) 新規鎮痛剤
EP1959988B1 (en) Use of bovine lactoferrin for treating destructive inflammation of mucous membrane
JP2009501801A5 (https=)
Majewski A current opinion on the safety and efficacy of doxycycline including parenteral administration–A review
EP2338495A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
WO2021240293A1 (en) Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system
CN114585380A (zh) 胃肠健康组合物
US20030207819A1 (en) Compositions and methods for treating inflammatory connective tissue diseases
Chomczynski et al. Compositions and methods for anti-inflammatory treatments
AU2012230089B2 (en) Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
CA2849732A1 (en) Buffered upper gi absorption promoter
US7998476B2 (en) Method of treatment using Aspergillus oryzae protease
US4346095A (en) Therapeutic treatment for viral hepatitis infection
CA2129919C (en) Pharmaceutical composition having antiviral and antibacterial activity and method of administration
US8586537B2 (en) Method for treating minor aphthous ulcers
Serdar Edited by Serdar GÜL
US5527787A (en) Pharmaceutical composition having antiviral and antibacterial activity and method of administration
CN1033208C (zh) L－赖氨酸盐酸盐在制备止血药物中的应用
JP2003128574A (ja) コンアルブミンを有効成分とする腸溶性経口組成物
UA119855U (uk) Спосіб профілактики геморагічної хвороби новонароджених
CN107281462A (zh) 沙奎拉韦减轻伊立替康毒性的医药新用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120926